Erschienen:
Springer Science and Business Media LLC, 2023
Erschienen in:Scientific Reports
Sprache:
Englisch
DOI:
10.1038/s41598-023-39841-9
ISSN:
2045-2322
Entstehung:
Anmerkungen:
Beschreibung:
<jats:title>Abstract</jats:title><jats:p>Labile copper(II) ions (Cu<jats:sup>2+</jats:sup>) in serum are considered to be readily available for cellular uptake and to constitute the biologically active Cu<jats:sup>2+</jats:sup> species in the blood. It might also be suitable to reflect copper dyshomeostasis during diseases such as Wilson’s disease (WD) or neurological disorders. So far, no direct quantification method has been described to determine this small Cu<jats:sup>2+</jats:sup> subset. This study introduces a fluorometric high throughput assay using the novel Cu<jats:sup>2+</jats:sup> binding fluoresceine-peptide sensor FP4 (Kd of the Cu<jats:sup>2+</jats:sup>-FP4-complex 0.38 pM) to determine labile Cu<jats:sup>2+</jats:sup> in human and rat serum. Using 96 human serum samples, labile Cu<jats:sup>2+</jats:sup>was measured to be 0.14 ± 0.05 pM, showing no correlation with age or other serum trace elements. No sex-specific differences in labile Cu<jats:sup>2+</jats:sup> concentrations were noted, in contrast to the total copper levels in serum. Analysis of the effect of drug therapy on labile Cu<jats:sup>2+</jats:sup> in the sera of 19 patients with WD showed a significant decrease in labile Cu<jats:sup>2+</jats:sup> following copper chelation therapy, suggesting that labile Cu<jats:sup>2+</jats:sup> may be a specific marker of disease status and that the assay could be suitable for monitoring treatment progress.</jats:p>